Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
Combined positive score status in metastatic triple-negative breast cancer patients treated with sacituzumab govitecan: associated clinical characteristics and testing patterns in a Central European cohort.
СтатьяМногоцентровое исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Winsko-Szczęsnowicz Karolina, Pieniążek Małgorzata, Polakiewicz-Gilowska Anna, Kubeczko Marcin, Holánek Miloš, Malejčíková Miroslava, Soumarová Renáta, Študentová Hana, Konieczna Aleksandra, Młodzińska Agnieszka, Żubrowska Justyna, Lisik-Habib Maja, Pękala Anika, Krejčí Daniel, Šustr Jan, Kolářová Iveta, Danielewicz Iwona, Szymanik-Resko Magdalena, Ciszewski Tomasz, Rusinová Lenka, Czartoryska-Arłukowicz Bogumiła, Łacko Aleksandra, Jarząb Michał, Bielčiková Zuzana, Pacholczak-Madej Renata, Püsküllüoğlu Mirosława
Аннотация
BACKGROUND: Programmed death ligand 1 (PD-L1) expression, assessed by the combined positive score (CPS), is an established predictive biomarker for first-line chemo-immunotherapy in metastatic triple-negative breast cancer (mTNBC). In routine practice, CPS testing is heterogeneous and its relationship with outcomes in later-line, sacituzumab govitecan (SG)-treated patients with mTNBC is not well described. We aimed to assess clinicopathological correlates of CPS and its association with survival in this cohort.
METHODS: We conducted a retrospective, multicenter study within the Central European Breast Cancer Collaboration (CEBCC)-102 project. CPS was locally assessed by validated immunohistochemistry. Survival outcomes: overall survival (OS), post-metastatic survival (PMS), and metastasis-free interval, were assessed with the Kaplan-Meier method.
RESULTS: Of 303 women from the Czech Republic, Poland, and Slovakia with mTNBC treated with SG in ≥ 2 line, 107 (35.3%) with available CPS results were included in this analysis. CPS was positive (≥ 10) in 51/107 patients (47.7%) without significant demographic or disease-specific differences. During a median follow-up of 40 months, CPS-positive status may suggest worse outcomes in this cohort in multivariate analysis despite partial first-line chemo-immunotherapy exposure: OS 41.6 versus 67.7 months (HR 2.2, 95% CI: 1.1-4.5, p = 0.027) and PMS 20.2 versus 27.1 months (HR = 2.3, 95% CI: 1.2-4.2, p = 0.009).
CONCLUSIONS: In this selected cohort, CPS status did not correlate with clinicopathological characteristics, but CPS-positive status was associated with inferior survival outcomes. Given the selection and survivor bias inherent to later-line treatment cohorts and the incomplete availability of CPS, these findings should be considered hypothesis-generating.
METHODS: We conducted a retrospective, multicenter study within the Central European Breast Cancer Collaboration (CEBCC)-102 project. CPS was locally assessed by validated immunohistochemistry. Survival outcomes: overall survival (OS), post-metastatic survival (PMS), and metastasis-free interval, were assessed with the Kaplan-Meier method.
RESULTS: Of 303 women from the Czech Republic, Poland, and Slovakia with mTNBC treated with SG in ≥ 2 line, 107 (35.3%) with available CPS results were included in this analysis. CPS was positive (≥ 10) in 51/107 patients (47.7%) without significant demographic or disease-specific differences. During a median follow-up of 40 months, CPS-positive status may suggest worse outcomes in this cohort in multivariate analysis despite partial first-line chemo-immunotherapy exposure: OS 41.6 versus 67.7 months (HR 2.2, 95% CI: 1.1-4.5, p = 0.027) and PMS 20.2 versus 27.1 months (HR = 2.3, 95% CI: 1.2-4.2, p = 0.009).
CONCLUSIONS: In this selected cohort, CPS status did not correlate with clinicopathological characteristics, but CPS-positive status was associated with inferior survival outcomes. Given the selection and survivor bias inherent to later-line treatment cohorts and the incomplete availability of CPS, these findings should be considered hypothesis-generating.